Wave Life Sciences at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
Wave Life Sciences brings 7 presentations to ObesityWeek 2026 in National Harbor, and exhibits at Booth 428. Its program centers on body composition as a measure of treatment success and on the INHBE-activin E pathway as an obesity target. Its most concrete work shows that silencing Inhbe with a GalNAc-SpiNA siRNA drives tissue remodeling and a healthier metabolic profile.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
Wave Life Sciences Cambridge, MA | ◇Bronze Sponsor |
RNA medicines company whose pipeline includes WVE-007 for obesity, plus programs in alpha-1 antitrypsin deficiency and PNPLA3-linked liver disease. | Booth Exhibiting at Booth 428 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Talk Sat Nov 14 11:45am–1:15pm Rethinking Success in the Treatment of Overweight and Obesity Through Body Composition: What Are We Made of? Asks whether body composition, not weight loss alone, should measure obesity treatment success, and reviews activin E biology and small interfering RNA drugs. Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 11:55am–12:10pm Changing the Treatment Paradigm in Overweight and Obesity Management Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 12:10pm–12:35pm Beyond The Scale: The Clinical Relevance of Body Composition, Body Fat Distribution and Lean Mass Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 12:35pm–1:00pm From Genetic Evidence to Therapeutic Hypothesis: the INHBE-Activin E Pathway as a Target for Obesity Management Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 1:10pm–1:15pm Rethinking Success: Where Should Obesity Treatment Go? Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 4:30pm–4:45pm Poster Sun Nov 15 2:30pm–3:30pm Interim Data From INLIGHT: A Phase 1 Study of WVE-007 in Adults Living With Overweight and Obesity Obesity pharmacotherapy and drug developmentInterventional and clinical studies |
Find decision makers at Wave Life Sciences
Tell us what you sell and we’ll find the people at Wave Life Sciences most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction